+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Wet Age-Related Macular Degeneration Clinical Trial Pipeline Highlights - 2021

  • ID: 5236039
  • Report
  • January 2021
  • Region: Global
  • Fore Pharma
1 of 3
The latest report Wet Age-Related Macular Degeneration Pipeline Highlights - 2021, provides the most up-to-date information on key pipeline products in the global Wet Age-Related Macular Degeneration market. It covers emerging therapies for Wet Age-Related Macular Degeneration in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:
The report provides Wet Age-Related Macular Degeneration pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:
The report provides Wet Age-Related Macular Degeneration pipeline products by their dominant mechanism of action/drug class. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:
The report provides Wet Age-Related Macular Degeneration pipeline products by the company.

Short-term Launch Highlights:
Find out which Wet Age-Related Macular Degeneration pipeline products will be launched in the US and Ex-US till 2025.

SUMMARY:
  • Wet Age-Related Macular Degeneration phase 3 clinical trial pipeline products
  • Wet Age-Related Macular Degeneration phase 2 clinical trial pipeline products
  • Wet Age-Related Macular Degeneration phase 1 clinical trial pipeline products
  • Wet Age-Related Macular Degeneration preclinical research pipeline products
  • Wet Age-Related Macular Degeneration discovery stage pipeline products
  • Wet Age-Related Macular Degeneration pipeline products short-term launch highlights
Note: Product cover images may vary from those shown
2 of 3
1. Wet Age-Related Macular Degeneration Pipeline by Stages
2. Wet Age-Related Macular Degeneration Phase 3 Clinical Trial Insights
3. Wet Age-Related Macular Degeneration Phase 2 Clinical Trial Insights
4. Wet Age-Related Macular Degeneration Phase 1 Clinical Trial Insights
5. Wet Age-Related Macular Degeneration Preclinical Research Insights
6. Wet Age-Related Macular Degeneration Discovery Stage Insights
7. Appendix
8. Research Methodology

List of Tables
Table 1: Wet Age-Related Macular Degeneration Phase 3 Clinical Trials, 2021
Table 2: Wet Age-Related Macular Degeneration Phase 2 Clinical Trials, 2021
Table 3: Wet Age-Related Macular Degeneration Phase 1 Clinical Trials, 2021
Table 4: Wet Age-Related Macular Degeneration Preclinical Research, 2021
Table 5: Wet Age-Related Macular Degeneration Discovery Stage, 2021

List of Figures
Figure 1: Wet Age-Related Macular Degeneration Pipeline Molecules by Clinical Trials Stage, 2021
Figure 2: Wet Age-Related Macular Degeneration Phase 3 Clinical Trial Highlights, 2021
Figure 3: Wet Age-Related Macular Degeneration Phase 2 Clinical Trial Highlights, 2021
Figure 4: Wet Age-Related Macular Degeneration Phase 1 Clinical Trial Highlights, 2021
Figure 5: Wet Age-Related Macular Degeneration Preclinical Research Highlights, 2021
Figure 6: Wet Age-Related Macular Degeneration Discovery Stage Highlights, 2021
Note: Product cover images may vary from those shown
3 of 3
  • Global
  • Europe
  • US
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Japan
Note: Product cover images may vary from those shown
Adroll
adroll